PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 11/01/2012 -- Pain Therapeutics Inc. (NASDAQ:PTIE) is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma.Pain Therapeutics (NasdaqNM:PTIE) is -1.45 - -31.05% from the previous close of $4.67. It traded between $3.17 - 4.85 with total traded volume of 1213886 shares. Keep a close eye on PTIE, as the stock has been showing unusual moves over the past weeks. At Current market price, PTIE has recovered -5.57% from its 52-week Low of 3.41 and has Pulled back -45.05% from its 52-week high of 5.86.
For a FREE INSTANT ANALYSIS of PTIE, Please Visit
Savient Pharmaceuticals, Inc.(NASDAQ:SVNT) shares dropped 13.53% to $1.47. The company announced today that the Company’s third quarter 2012 financial results will be released prior to the market open on Thursday, November 8, 2012. Savient’s executive management will host a conference call beginning at 9:00 a.m. Eastern Time on November 8, 2012, to discuss these results and to answer questions. Shares of Savient Pharmaceu (NGM: SVNT) are trading at $1.6699 and is -23.05% of its 50-day Moving Average price of $2.17 and +26.00% from its 200-day Moving Average price of $1.3254. The average trading volume is 3222420 shares and its market capitalization is $118.4M.
Should Investors Buy SVNT Now? Find out where SVNT is headed next with a FREE TREND ANALYSIS REPORT
Community Health Systems Inc. (CYH) is an operator of hospitals in the United States. The Company provides healthcare services through the hospitals that it owns and operates in non-urban and selected urban markets throughout the United States. Community Health Systems (CYH), it had an amazing 76% rally from $17.05 to $30. Now, after an almost 11% correction to $26.79, I believe it's time to start rallying again. Last year's earnings ($280 million) were $3.15 per share while for 2012 EPS is expected around $3.5. To calculate EPS I used diluted shares outstanding as of June 30,2012. This is because the company is doing a lot of share buybacks. They have reduced the diluted shares outstanding from 108,378,131, at the end of 2002, to 89,281,868 at the end of Q2 2012.
How Should Investors React To CYH Now? Find Out Here
Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Incyte (NASDAQ: INCY) released its earnings data on Thursday. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. The company had revenue of $60.50 million for the quarter, compared to the consensus estimate of $60.61 million. Incyte’s revenue was up 260.5% compared to the same quarter last year.
How Should Investors React To INCY Now? Check here
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)